Skip to main content
SpringerLink
Log in

Small Cell Lung Cancer

  • Chapter
  • First Online:
60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center

Abstract

Small cell lung cancer (SCLC) accounts for about 13 % of all lung cancer cases, with about 29,000 new cases diagnosed annually in the USA [1]. The incidence of SCLC is declining, due in part to decreased smoking rates, increased use of filtered cigarettes, and changes in pathologic criteria for classifying SCLC [2].

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 89.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 119.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 169.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. American Cancer Society. Cancer facts and figures 2009. Atlanta: American Cancer Society; 2009.

    Google Scholar 

  2. Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24:4539–44.

    Article  PubMed  Google Scholar 

  3. Micke P, Faldun A, Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer – what limits limited disease? Lung Cancer. 2002;37:271–6.

    Article  PubMed  Google Scholar 

  4. List AF, Hainsworth JD, Davis BW, Hande KR, Greco FA, Johnson DH. The syndrome of inappropriate secretion of antidiuretic hormone (SIADH) in small-cell lung cancer. J Clin Oncol. 1986;4:1191–8.

    PubMed  CAS  Google Scholar 

  5. Yip D, Harper PG. Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer. 2000;28:173–85.

    Article  PubMed  CAS  Google Scholar 

  6. Shepherd FA, Laskey J, Evans WK, Goss PE, Johansen E, Khamsi F. Cushing’s syndrome associated with ectopic corticotropin production and small-cell lung cancer. J Clin Oncol. 1992;10:21–7.

    PubMed  CAS  Google Scholar 

  7. Hanrahan EO, Glisson B. Small cell carcinoma of the lung. In: Stewart D, editor. Lung cancer: prevention, management, and emerging therapies. Houston: The University of Texas MD Anderson Cancer Center; 2010. p. 395–434.

    Google Scholar 

  8. Green RA, Humphrey E, Close H, Patno ME. Alkylating agents in bronchogenic carcinoma. Am J Med. 1969;46:516–25.

    Article  PubMed  CAS  Google Scholar 

  9. Evans WK, Shepherd FA, Feld R, Osoba D, Dang P, Deboer G. VP-16 and cisplatin as first-line therapy for small-cell lung cancer. J Clin Oncol. 1985;3:1471–7.

    PubMed  CAS  Google Scholar 

  10. Evans WK, Feld R, Murray N, et al. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Cancer. Ann Intern Med. 1987;107:451–8.

    PubMed  CAS  Google Scholar 

  11. Fukuoka M, Furuse K, Saijo N, et al. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer. J Natl Cancer Inst. 1991;83:855–61.

    Article  PubMed  CAS  Google Scholar 

  12. Roth BJ, Johnson DH, Einhorn LH, et al. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase II trial of the Southeastern Cancer Study Group. J Clin Oncol. 1992;10:282–91.

    PubMed  CAS  Google Scholar 

  13. Feld R, Evans WK, Coy P, et al. Canadian multicenter randomized trial comparing sequential and alternating administration of two non-cross-resistant chemotherapy combinations in patients with limited small-cell carcinoma of the lung. J Clin Oncol. 1987;5:1401–9.

    PubMed  CAS  Google Scholar 

  14. Goodman GE, Crowley JJ, Blasko JC, et al. Treatment of limited small-cell lung cancer with etoposide and cisplatin alternating with vincristine, doxorubicin, and cyclophosphamide versus concurrent etoposide, vincristine, doxorubicin, and cyclophosphamide and chest radiotherapy: a Southwest Oncology Group Study. J Clin Oncol. 1990;8:39–47.

    PubMed  CAS  Google Scholar 

  15. Hanna N, Ansari R, Fisher W, Shen J, Jung SH, Sandler A. Etoposide, ifosfamide, and cisplatin (VIP) plus concurrent radiotherapy for previously untreated limited small cell lung cancer: a Hoosier Oncology Group (HOG) phase II study. Lung Cancer. 2002;35:293–7.

    Article  PubMed  Google Scholar 

  16. Niell HB, Herndon JE, Miller AA, et al. Randomized phase II intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: cancer and leukemia group B trial 9732. J Clin Oncol. 2005;23:3752–9.

    Article  PubMed  CAS  Google Scholar 

  17. Mavroudis D, Papadakis E, Veslemes M, et al. A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol. 2001;12:463–70.

    Article  PubMed  CAS  Google Scholar 

  18. Reck M, von Pawel J, Macha HN, et al. Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small cell lung cancer. J Natl Cancer Inst. 2003;95:1118–27.

    Article  PubMed  CAS  Google Scholar 

  19. Noda K, Nishiwaki Y, Kawahara M, et al. Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med. 2002;346:85–91.

    Article  PubMed  CAS  Google Scholar 

  20. Hanna N, Bunn PA, Langer C, et al. Randomized phase III trial comparing cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol. 2006;24:2038–43.

    Article  PubMed  CAS  Google Scholar 

  21. Natale RB, Lara PN, Chansky K, et al. S0124: a randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive stage small cell lung cancer [abstract 7512]. J Clin Oncol. 2008;26 Suppl 15:7512.

    Google Scholar 

  22. Hermes A, Bergman B, Bremnes R, et al. Irinotecan plus carboplatin versus oral etoposide plus carboplatin in extensive small-cell lung cancer: a randomized phase III trial. J Clin Oncol. 2008;26:4261–7.

    Article  PubMed  CAS  Google Scholar 

  23. Eckardt JR, von Pawel J, Papai Z, et al. Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy-naïve patients with extensive-disease small-cell lung cancer. J Clin Oncol. 2006;24:2044–51.

    Article  PubMed  CAS  Google Scholar 

  24. Fukuoka M, Masuda N, Negoro S, et al. CODE chemotherapy with and without granulocyte colony-stimulating factor in small-cell lung cancer. Br J Cancer. 1997;75:306–9.

    Article  PubMed  CAS  Google Scholar 

  25. Steward WP, von Pawel J, Gatzemeier U, et al. Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol. 1998;16:642–50.

    PubMed  CAS  Google Scholar 

  26. Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ. Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. J Clin Oncol. 2000;18:395–404.

    PubMed  CAS  Google Scholar 

  27. Buchholz E, Manegold C, Pilz L, Thatcher N, Drings P. Standard versus dose-intensified chemotherapy with sequential reinfusion of hematopoietic progenitor cells in small cell lung cancer patients with favorable prognosis. J Thorac Oncol. 2007;2:51–8.

    Article  PubMed  Google Scholar 

  28. Lorigan P, Woll PJ, O’Brien ME, Ashcroft LF, Sampson MR, Thatcher N. Randomized phase III trial of dose-dense chemotherapy supported by whole-blood hematopoietic progenitors in better-prognosis small-cell lung cancer. J Natl Cancer Inst. 2005;97:666–74.

    Article  PubMed  CAS  Google Scholar 

  29. Ihde DC, Mulshine JL, Kramer BS, et al. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small-cell lung cancer. J Clin Oncol. 1994;12:2022–34.

    PubMed  CAS  Google Scholar 

  30. Heigener DF, Manegold C, Jäger E, Saal JG, Zuna I, Gatzemeier U. Multicenter randomized open-label phase III study comparing efficacy, safety, and tolerability of conventional carboplatin plus etoposide versus dose-intensified carboplatin plus etoposide plus lenograstim in small-cell lung cancer in extensive disease stage. Am J Clin Oncol. 2009;32:61–4.

    Article  PubMed  CAS  Google Scholar 

  31. Klasa RJ, Murray N, Coldman AJ. Dose-intensity meta-analysis of chemotherapy regimens in small-cell carcinoma of the lung. J Clin Oncol. 1991;9:499–508.

    PubMed  CAS  Google Scholar 

  32. Hanna NH, Sandler AB, Loehrer PJ, et al. Maintenance daily oral etoposide versus no further therapy following induction chemotherapy with etoposide plus ifosfamide plus cisplatin in extensive small-cell lung cancer: a Hoosier Oncology Group randomized study. Ann Oncol. 2002;13:95–102.

    Article  PubMed  CAS  Google Scholar 

  33. Schiller JH, Adak S, Cella D, DeVore RF, Johnson DH. Topotecan versus observation after cisplatin plus etoposide in extensive-stage small cell lung cancer: E7593 – a phase III trial of the Eastern Cooperative Oncology Group. J Clin Oncol. 2001;19:2114–22.

    PubMed  CAS  Google Scholar 

  34. Arriagada R, Le Chevalier T, Pignon JP, et al. Initial chemotherapeutic doses and survival in patients with limited small-cell lung cancer. N Engl J Med. 1993;329:1848–52.

    Article  PubMed  CAS  Google Scholar 

  35. Murray N, Coy P, Pater JL, et al. Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol. 1993;11:336–44.

    PubMed  CAS  Google Scholar 

  36. Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S. Initial versus delayed accelerated hyperfractionated radiation therapy and concurrent chemotherapy in limited small-cell lung cancer: a randomized study. J Clin Oncol. 1997;15:893–900.

    PubMed  CAS  Google Scholar 

  37. Turrisi AT, Kim K, Blum R, et al. Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med. 1999;340:265–71.

    Article  PubMed  CAS  Google Scholar 

  38. Pöttgen C, Eberhardt W, Stuschke M. Prophylactic cranial irradiation in lung cancer. Curr Treat Options Oncol. 2004;5:43–50.

    Article  PubMed  Google Scholar 

  39. Aupérin A, Arriagada R, Pignon JP, et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med. 1999;341:476–84.

    Article  PubMed  Google Scholar 

  40. Slotman B, Faivre-Finn C, Kramer G, et al. Prophylactic cranial irradiation in extensive small-cell lung cancer. N Engl J Med. 2007;357:664–72.

    Article  PubMed  CAS  Google Scholar 

  41. Fonseca R, O’Neill BP, Foote RL, Grill JP, Sloan JA, Frytak S. Cerebral toxicity in patients treated for small cell carcinoma of the lung. Mayo Clin Proc. 1999;74:461–5.

    PubMed  CAS  Google Scholar 

  42. Postmus PE, Berendsen HH, van Zandwijk N, Splinter TA, Burghouts JT, Bakker W. Retreatment with the induction regimen in small cell lung cancer relapsing after an initial response to short term chemotherapy. Eur J Cancer Clin Oncol. 1987;23:1409–11.

    Article  PubMed  CAS  Google Scholar 

  43. Giaccone G, Ferrati P, Donadio M, Testore F, Calciati A. Reinduction chemotherapy in small cell lung cancer. Eur J Cancer Clin Oncol. 1987;23:1697–9.

    Article  PubMed  CAS  Google Scholar 

  44. Vincent M, Evans B, Smith I. First-line chemotherapy rechallenge after relapse in small cell lung cancer. Cancer Chemother Pharmacol. 1988;21:45–8.

    PubMed  CAS  Google Scholar 

  45. Giaccone G, Donadio M, Bonardi G, Testore F, Calciati A. Teniposide in the treatment of small-cell lung cancer: the influence of prior chemotherapy. J Clin Oncol. 1988;6:1264–70.

    PubMed  CAS  Google Scholar 

  46. Batist G, Ihde DC, Zabell A, et al. Small-cell carcinoma of the lung: reinduction therapy after late relapse. Ann Intern Med. 1983;98:472–4.

    PubMed  CAS  Google Scholar 

  47. Eckardt JR, von Pawel J, Pujol JL, et al. Phase III study of oral compared with intravenous topotecan as second-line therapy in small-cell lung cancer. J Clin Oncol. 2007;25:2086–92.

    Article  PubMed  CAS  Google Scholar 

  48. von Pawel J, Schiller JH, Shepherd FA, et al. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol. 1999;17:658–67.

    Google Scholar 

  49. O’Brien ME, Ciuleanu TE, Tsekov H, et al. Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol. 2006;24:5441–7.

    Article  PubMed  Google Scholar 

  50. Ardizzoni A, Manegold C, Debruyne C, et al. European Organization for Research and Treatment of Cancer (EORTC) 08957: phase II study of topotecan in combination with cisplatin as second line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res. 2003;9:143–50.

    PubMed  CAS  Google Scholar 

  51. Eckardt J, Gralla R, Palmer MC, et al. Topotecan as second line therapy in patients with small cell lung cancer: a phase II study [abstract 513P]. Ann Oncol. 1996;7:107.

    Article  Google Scholar 

  52. Depierre A, von Pawel J, Hans K, et al. Evaluation of topotecan in relapsed small cell lung cancer. A multicentre phase II study [abstract]. Lung Cancer. 1997;18:35.

    Article  Google Scholar 

  53. von Pawel J, Gatzemeier U, Pujol JL, et al. Phase II comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol. 1999;19:1743–9.

    Google Scholar 

  54. Masuda N, Fukuoka M, Kusunoki Y, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol. 1992;10:1225–9.

    PubMed  CAS  Google Scholar 

  55. Joos G, Schallier D, Pinson P, et al. Paclitaxel as second line treatment in patients with small cell lung cancer refractory to carboplatin-etoposide: a multicenter phase II study [abstract 7211]. Proc ASCO. 2004. pp. 22.

    Google Scholar 

  56. Smit EF, Fokkema E, Biesma B, Groen HJ, Snoek W, Postmus PE. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer. Br J Cancer. 1998;77:347–51.

    Article  PubMed  CAS  Google Scholar 

  57. Smyth JF, Smith IE, Sessa C, et al. Activity of docetaxel (Taxotere) in small cell lung cancer. The Early Clinical Trials Group of the EORTC. Eur J Cancer. 1994;30:1058–60.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Thoracic/Head and Neck Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 432, Houston, TX, 77030, USA

    Frank V. Fossella

Authors
  1. Frank V. Fossella
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Frank V. Fossella .

Editor information

Editors and Affiliations

  1. Department of Lymphoma and Myeloma, University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA

    M. Alma Rodriguez

  2. Department of Breast Medical Oncology, University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA

    Ronald S. Walters

  3. Department of Gynecologic Oncology, University of Texas MD Anderson Cancer Center, Houston, 77030, Texas, USA

    Thomas W. Burke

Rights and permissions

Reprints and permissions

Copyright information

© 2013 Springer Science+Business Media New York

About this chapter

Cite this chapter

Fossella, F.V. (2013). Small Cell Lung Cancer. In: Rodriguez, M., Walters, R., Burke, T. (eds) 60 Years of Survival Outcomes at The University of Texas MD Anderson Cancer Center. Springer, New York, NY. https://doi.org/10.1007/978-1-4614-5197-6_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4614-5197-6_7

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4614-5196-9

  • Online ISBN: 978-1-4614-5197-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation